SCHEMBL5848719

SCHEMBL5848719

CC(C)C[C@H](NC(=O)c1ccccc1)C(=O)CN1CCCc2ccccc2C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.52
KMT2A Q03164 3/20 0.49
TAOK1 Q7L7X3 1/20 0.49
TAOK3 Q9H2K8 1/20 0.49
HDAC1 Q13547 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
CTSK P43235 4/20 0.47
CCR1 P32246 2/20 0.46
CTSL P07711 3/20 0.46
CTSS P25774 2/20 0.46
CTSB P07858 1/20 0.46
MEN1 O00255 2/20 0.45
MAPT P10636 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PRMT5 O14744 2/20 0.45
WDR77 Q9BQA1 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
CARM1 Q86X55 1/20 0.43
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5848546 0.90 KMT2A (0.44) POLBKMT2ATAOK1TAOK3HDAC1
SCHEMBL5850031 0.88 POLB (0.50) POLBKMT2ATAOK1TAOK3HDAC1
SCHEMBL5848770 0.86 GPR132 (0.51) POLBKMT2ACTSKMEN1MAPT
SCHEMBL5848493 0.85 TAOK1 (0.43) POLBKMT2ATAOK1TAOK3HDAC1
SCHEMBL6867039 0.85 TAOK1 (0.43) POLBKMT2ATAOK1TAOK3HDAC1
SCHEMBL5848743 0.85 TAOK1 (0.43) POLBKMT2ATAOK1TAOK3HDAC1
SCHEMBL5848731 0.85 TAOK1 (0.43) POLBKMT2ATAOK1TAOK3HDAC1
SCHEMBL5850513 0.85 TAOK1 (0.43) POLBKMT2ATAOK1TAOK3HDAC1
SCHEMBL5850375 0.85 CARM1 (0.48) POLBCTSKCTSLCTSSMAPT
SCHEMBL5848783 0.83 DRD2 (0.48) POLBKMT2AHDAC1HDAC6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162964-A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient NOKIA CORPORATION (FI) 2003-08-28 US claimed
EP-1254898-A1 BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-11-06 EP claimed
US-7008938-B2 Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient NOKIA CORPORATION (FI) 2006-03-07 US disclosed
US-20050009755-A1 Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. 2005-01-13 US disclosed
US-6809092-B2 1,3,4,5-TETRAHYDRO-2H-2-BENZAZEPIN-2-YL DERIVATIVES; CYSTEINE PROTEASE INHIBITORS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-10-26 US disclosed
US-20030162964-A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient NOKIA CORPORATION (FI) 2003-08-28 US disclosed
EP-1254898-A1 BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162964-A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient BACH1, BACE1, CMA1 POLB 1900/4885KMT2A 4469/4885TAOK1 2279/4885
US-20050009755-A1 Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient BACE1, BACE2, CBS POLB 1435/4885KMT2A 4517/4885TAOK1 2998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.